InsidersTradesSigma
Follow the BETA BIONICS INC stock price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €887.2m. The latest transaction was disclosed on 3 September 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Sean Saint. Every trade is openly available.
Analysts rate BETA BIONICS INC Buy (bullish), based on 11 analysts. Average price target: US$20.31.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
BETA BIONICS INC es una empresa centrada en el desarrollo de dispositivos médicos para el manejo de la diabetes. Su objetivo es aprovechar la innovación tecnológica para mejorar la calidad de vida de los pacientes.